|
NARG2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
2.63730004501639E-09 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62536650805123E-12 |
| Stage1-vs-Stage2 |
9.412000E-01 |
| Stage1-vs-Stage3 |
2.131500E-02 |
| Stage1-vs-Stage4 |
8.385200E-04 |
| Stage2-vs-Stage3 |
1.124440E-01 |
| Stage2-vs-Stage4 |
1.823980E-02 |
| Stage3-vs-Stage4 |
2.743400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.24975635080227E-14 |
| Normal-vs-AfricanAmerican |
6.33329999999432E-05 |
| Normal-vs-Asian |
2.11030082297725E-11 |
| Caucasian-vs-AfricanAmerican |
5.876500E-02 |
| Caucasian-vs-Asian |
6.086400E-01 |
| AfricanAmerican-vs-Asian |
1.783360E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.26085858104852E-14 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
3.064400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.6251444634463E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62536650805123E-12 |
| Normal-vs-Age(81-100Yrs) |
9.76630000000256E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.853220E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.706970E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.243800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.023800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.758200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.368200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.856690E-03 |
| Classical-VS-Follicular |
8.519600E-01 |
| Classical-VS-Other |
5.054400E-01 |
| Classical-VS-Normal |
1.51120227442902E-11 |
| Tall-VS-Follicular |
6.782400E-03 |
| Tall-VS-Other |
4.435600E-01 |
| Tall-VS-Normal |
3.98570065840431E-14 |
| Follicular-VS-Other |
5.373000E-01 |
| Follicular-VS-Normal |
4.58509896716919E-11 |
| Other-VS-Normal |
5.627400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
2.1538326677728E-14 |
| N0-vs-N1 |
7.946500E-02 |
|
|
